These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

346 related items for PubMed ID: 23427864

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
    Charbonnel B, Karasik A, Liu J, Wu M, Meininger G, Sitagliptin Study 020 Group.
    Diabetes Care; 2006 Dec; 29(12):2638-43. PubMed ID: 17130197
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes.
    Williams-Herman D, Johnson J, Teng R, Golm G, Kaufman KD, Goldstein BJ, Amatruda JM.
    Diabetes Obes Metab; 2010 May; 12(5):442-51. PubMed ID: 20415693
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile: a 2-year study evaluation.
    Derosa G, Ragonesi PD, Fogari E, Cicero AF, Bianchi L, Bonaventura A, Romano D, Maffioli P.
    Fundam Clin Pharmacol; 2014 Apr; 28(2):221-9. PubMed ID: 23039403
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin.
    Maffioli P, Fogari E, D'Angelo A, Perrone T, Derosa G.
    Eur J Gastroenterol Hepatol; 2013 Sep; 25(9):1113-22. PubMed ID: 23524525
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Combination treatment with metformin and glibenclamide versus single-drug therapies in type 2 diabetes mellitus: a randomized, double-blind, comparative study.
    Tosi F, Muggeo M, Brun E, Spiazzi G, Perobelli L, Zanolin E, Gori M, Coppini A, Moghetti P.
    Metabolism; 2003 Jul; 52(7):862-7. PubMed ID: 12870162
    [Abstract] [Full Text] [Related]

  • 39. Efficacy and safety of adding pioglitazone or sitagliptin to patients with type 2 diabetes insufficiently controlled with metformin and a sulfonylurea.
    Liu SC, Chien KL, Wang CH, Chen WC, Leung CH.
    Endocr Pract; 2013 Jul; 19(6):980-8. PubMed ID: 23807528
    [Abstract] [Full Text] [Related]

  • 40. Effect of initial combination therapy with sitagliptin and metformin on β-cell function in patients with type 2 diabetes.
    Williams-Herman D, Xu L, Teng R, Golm GT, Johnson J, Davies MJ, Kaufman KD, Goldstein BJ.
    Diabetes Obes Metab; 2012 Jan; 14(1):67-76. PubMed ID: 22050786
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.